BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fried MW. Side effects of therapy of hepatitis C and their management: Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:s237-44. [DOI: 10.1053/jhep.2002.36810] [Cited by in Crossref: 59] [Cited by in F6Publishing: 207] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol 2013;8:1469-78. [PMID: 23594083 DOI: 10.1021/cb400100g] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
2 Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005;12:223-235. [PMID: 15850462 DOI: 10.1111/j.1365-2893.2005.00600.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
3 Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75:931-43. [PMID: 22882367 DOI: 10.1111/j.1365-2125.2012.04419.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
4 Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013;87:3741-51. [PMID: 23325689 DOI: 10.1128/JVI.02346-12] [Cited by in Crossref: 214] [Cited by in F6Publishing: 121] [Article Influence: 26.8] [Reference Citation Analysis]
5 Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. Factors that influence an HIV coinfected patient’s decision to start hepatitis C treatment. AIDS Patient Care STDS. 2009;23:993-999. [PMID: 19929229 DOI: 10.1089/apc.2009.0153] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
6 Meyer MF, Wedemeyer H, Monazahian M, Dreesman J, Manns MP, Lehmann M. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiol Infect 2007;135:274-80. [PMID: 16824250 DOI: 10.1017/S0950268806006820] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
7 Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2003;63:701-730. [PMID: 12656650 DOI: 10.2165/00003495-200363070-00008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
8 Nagao Y, Sata M. Dental problems delaying the initiation of interferon therapy for HCV-infected patients. Virol J 2010;7:192. [PMID: 20712912 DOI: 10.1186/1743-422X-7-192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. [PMID: 22910833 DOI: 10.1371/journal.ppat.1002832] [Cited by in Crossref: 149] [Cited by in F6Publishing: 108] [Article Influence: 16.6] [Reference Citation Analysis]
10 Shoreibah M, Orr J, Jones D, Zhang J, Venkata K, Massoud O. Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. Hepatol Int 2017;11:434-9. [PMID: 28083718 DOI: 10.1007/s12072-016-9778-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20. [PMID: 15951552 DOI: 10.1136/gut.2004.057893] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
12 Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA. 2011;108:3719-3724. [PMID: 21321200 DOI: 10.1073/pnas.1100349108] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
13 Bani-Sadr F, Lapidus N, Melchior JC, Ravaux I, Bensalem M, Rosa I, Cacoub P, Pol S, Perronne C, Carrat F. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat. 2008;15:255-260. [PMID: 18307589 DOI: 10.1111/j.1365-2893.2007.00939.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
14 Marx J, Schwenger V, Blank N, Stremmel W, Encke J. [Hemoptysis and acute renal failure in a 29-year-old patient with chronic hepatitis C infection]. Internist (Berl) 2008;49:1120-5. [PMID: 18604512 DOI: 10.1007/s00108-008-2099-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
15 Deming P, Mcnicholl IR. Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus: Challenges and Therapeutic Advances Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2011;31:357-68. [DOI: 10.1592/phco.31.4.357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
16 Thai K, Dong Q, Nguyen T, Le D, Le M, Tran T. Computational Approaches for the Discovery of Novel Hepatitis C Virus NS3/4A and NS5B Inhibitors. In: Management Association IR, editor. Oncology. IGI Global; 2017. pp. 482-518. [DOI: 10.4018/978-1-5225-0549-5.ch017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Suzuki K, Tamano M, Katayama Y, Kuniyoshi T, Kagawa K, Takada H, Suzuki K. Study of pruritus in chronic hepatitis C patients. World J Gastroenterol 2014;20:17877-82. [PMID: 25548485 DOI: 10.3748/wjg.v20.i47.17877] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
18 Goncalves LL, Farias AQ, Gonçalves PL, D'Amico EA, Carrilho FJ. Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C. World J Gastroenterol 2006;12:4602-3. [PMID: 16874884 DOI: 10.3748/wjg.v12.i28.4602] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
19 Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep. 2004;6:17-21. [PMID: 14720449 DOI: 10.1007/s11894-004-0021-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
20 Blatt CR, Bernardo NLMDC, Rosa JA, Bagatini F, Alexandre RF, Balbinotto Neto G, Siebert U, Rocha Farias M. An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System. Value in Health Regional Issues 2012;1:129-35. [DOI: 10.1016/j.vhri.2012.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
21 O'Keefe-Markman C, Lea KD, McCabe C, Hyshka E, Bubela T. Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment. BMC Public Health 2020;20:89. [PMID: 31959155 DOI: 10.1186/s12889-020-8190-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005;21:1163-1171. [PMID: 15854180 DOI: 10.1111/j.1365-2036.2005.02453.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
23 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 18.0] [Reference Citation Analysis]
24 Lee MY, Chen WC, Hsu WH, Chen SC, Lee JC. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism. Int J Mol Sci 2019;20:E4569. [PMID: 31540136 DOI: 10.3390/ijms20184569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hlaing NK, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016;22:9613-22. [PMID: 27920482 DOI: 10.3748/wjg.v22.i43.9613] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007;52:1168-1176. [PMID: 17357838 DOI: 10.1007/s10620-006-9579-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
27 Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14:782-7. [DOI: 10.1111/j.1365-2893.2007.00870.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
28 Tajir M, Elmachad M, Kabbaj N, Laarabi FZ, Barkat A, Amrani N, Sefiani A. Frequency of IL28B rs12979860 single-nucleotide polymorphism alleles in newborn infants and in patients with chronic hepatitis C in Morocco. Genet Test Mol Biomarkers 2012;16:981-3. [PMID: 22509814 DOI: 10.1089/gtmb.2011.0353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
29 Daniel AL, Houlihan JL, Blum JS, Walsh JP. Type B insulin resistance developing during interferon-alpha therapy. Endocr Pract 2009;15:153-7. [PMID: 19289328 DOI: 10.4158/EP.15.2.153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
30 Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging 2016;11:327-34. [PMID: 27051280 DOI: 10.2147/CIA.S97242] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Helal TEA, Radwan NA, Mahmoud HA, Zaki AM, Ahmed NS, Wahib AA, Aref AM. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4. Afr Health Sci 2019;19:1411-21. [PMID: 31148968 DOI: 10.4314/ahs.v19i1.14] [Reference Citation Analysis]
32 Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights. 2015;10:25-52. [PMID: 26819546 DOI: 10.4137/bmi.s29512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
33 Castera L, Constant A, Henry C, Champbenoit P, Bernard PH, De Ledinghen V, Demotes-Mainard J, Couzigou P. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006;24:1223-30. [PMID: 17014581 DOI: 10.1111/j.1365-2036.2006.03107.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
34 Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse 2012;38:206-12. [PMID: 22242700 DOI: 10.3109/00952990.2011.643975] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
35 Lodato F, Tame MR, Colecchia A, Racchini C, Azzaroli F, D'Errico A, Casanova S, Pinna A, Roda E, Mazzella G. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006;12:4253-5. [PMID: 16830387 DOI: 10.3748/wjg.v12.i26.4253] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
36 Lee YC, Wang JL, Dong YH, Chen HC, Wu LC, Chang CH. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study. PLoS Med 2019;16:e1002894. [PMID: 31518344 DOI: 10.1371/journal.pmed.1002894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Marcellin F, Roux P, Winnock M, Lions C, Dabis F, Salmon-ceron D, Loko M, Spire B, Carrieri MP. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Expert Review of Gastroenterology & Hepatology 2014;8:351-8. [DOI: 10.1586/17474124.2014.888949] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
38 Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J. 2014;11:64. [PMID: 24690114 DOI: 10.1186/1743-422x-11-64] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
39 Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423-431. [PMID: 16341948 DOI: 10.1007/s11096-005-1319-7] [Cited by in Crossref: 129] [Cited by in F6Publishing: 101] [Article Influence: 8.6] [Reference Citation Analysis]
40 Chisholm JA, Williams G, Spence E, Parks S, Keating D, Gavin M, Mills PR. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Aliment Pharmacol Ther. 2005;21:723-732. [PMID: 15771758 DOI: 10.1111/j.1365-2036.2005.02365.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
41 Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016;33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M. Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27:957-965. [PMID: 22142332 DOI: 10.1111/j.1440-1746.2011.07035.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
43 Li S, Yang Y, Ding X, Yang M, She S, Peng H, Xu X, Ran X, Li S, Hu P, Hu H, Zhang D, Ren H. LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study. Oncotarget 2017;8:4549-62. [PMID: 27999186 DOI: 10.18632/oncotarget.13941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. Can J Gastroenterol Hepatol 2017;2017:3268650. [PMID: 28529936 DOI: 10.1155/2017/3268650] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
45 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol. 2014;20:2839-2853. [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009;30:14-27. [PMID: 19416131 DOI: 10.1111/j.1365-2036.2009.04004.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
47 Evon DM, Esserman DA, Ramcharran D, Bonner JE, Fried MW. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res 2011;71:349-56. [PMID: 21999979 DOI: 10.1016/j.jpsychores.2011.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
48 Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep. 2011;10:33-40. [PMID: 21423320 DOI: 10.1007/s11901-010-0078-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
49 Gupta R, Ramakrishna CH, Lakhtakia S, Tandan M, Banerjee R, Reddy DN. Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. World J Gastroenterol 2006;12:5554-6. [PMID: 17006999 DOI: 10.3748/wjg.v12.i34.5554] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
50 Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, Suzuki T, Tatsumi M, Moriishi K, Matsuura Y. Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules. PLoS One 2011;6:e15967. [PMID: 21253612 DOI: 10.1371/journal.pone.0015967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
51 Juanbeltz R, Martínez-Baz I, San Miguel R, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One 2018;13:e0205277. [PMID: 30300395 DOI: 10.1371/journal.pone.0205277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
52 Teixeira PA, Bresnahan MP, Laraque F, Litwin AH, Shukla SJ, Schwartz JM, Reynoso S, Perumalswami PV, Weiss JM, Wyatt B, Schackman BR. Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE. Learn Health Syst 2018;2:e10056. [PMID: 31106275 DOI: 10.1002/lrh2.10056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
53 Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZM, Hansen BE, Veldt BJ, Janssen HL, Boonstra A, de Knegt RJ. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. PLoS One 2015;10:e0139317. [PMID: 26441325 DOI: 10.1371/journal.pone.0139317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
54 Mendes LC, Stucchi RS, Vigani AG. Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepat Med. 2018;10:13-22. [PMID: 29662329 DOI: 10.2147/hmer.s125234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
55 Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A, Colecchia A. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004;10:12-6. [PMID: 14695760 DOI: 10.3748/wjg.v10.i1.12] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
56 Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology. 2010;51:1494-1504. [PMID: 20127796 DOI: 10.1002/hep.23401] [Cited by in Crossref: 137] [Cited by in F6Publishing: 131] [Article Influence: 12.5] [Reference Citation Analysis]
57 Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int 2009;29:366-73. [PMID: 18694403 DOI: 10.1111/j.1478-3231.2008.01833.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
58 Huang YW, Tsai CY, Tsai CW, Wang W, Zhang J, Qin A, Teng C, Song B, Wang MX. Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Adv Ther 2021;38:4756-70. [PMID: 34328630 DOI: 10.1007/s12325-021-01863-y] [Reference Citation Analysis]
59 Kraus MR, Schäfer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005;11:1769-74. [PMID: 15793861 DOI: 10.3748/wjg.v11.i12.1769] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
60 Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol 2015;7:1921-35. [PMID: 26244067 DOI: 10.4254/wjh.v7.i15.1921] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
61 Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70:147-165. [PMID: 20108989 DOI: 10.2165/11531990-000000000-00000] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
62 Rodell CB, Ahmed MS, Garris CS, Pittet MJ, Weissleder R. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics 2019;9:8426-36. [PMID: 31879528 DOI: 10.7150/thno.35434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
63 Zhang J, Garrison JC, Poluektova LY, Bronich TK, Osna NA. Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. Biomaterials 2015;70:37-47. [PMID: 26298393 DOI: 10.1016/j.biomaterials.2015.08.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
64 Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012;12:86. [PMID: 22494445 DOI: 10.1186/1471-2334-12-86] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
65 Kwon JH, Bae SH, Choi JY, Yoon SK, Byun KS, Paik SW, Lim YS, Lee HC, Han KH, Lee KS. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med 2009;24:203-11. [PMID: 19721856 DOI: 10.3904/kjim.2009.24.3.203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
66 Evon DM, Golin CE, Fried MW, Keefe FJ. Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol 2013;81:361-74. [PMID: 22730952 DOI: 10.1037/a0029030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
67 Chopra A, Marak C, Alappan N, Shim C. Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy. Case Rep Pulmonol 2015;2015:794592. [PMID: 25705538 DOI: 10.1155/2015/794592] [Reference Citation Analysis]
68 Nagao Y, Kawaguchi T, Ide T, Sata M. Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virol J 2012;9:282. [PMID: 23173649 DOI: 10.1186/1743-422X-9-282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
69 Gull I, Aslam MS, Tipu I, Mushtaq R, Ali TZ, Athar MA. Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection. Sci Rep 2019;9:10867. [PMID: 31350425 DOI: 10.1038/s41598-019-47074-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Dis. 2008;14:10-14. [PMID: 18173443 DOI: 10.1111/j.1601-0825.2007.01419.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
72 Sapra S, Chang E, Broder MS, L'Italien G. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 2014;14:429. [PMID: 25249187 DOI: 10.1186/1472-6963-14-429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
73 Pagliaccetti NE, Robek MD. Interferon-λ in HCV Infection and Therapy. Viruses 2010;2:1589-602. [PMID: 21994696 DOI: 10.3390/v2081589] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
74 Santos AED, Partovi N, Ford JE, Yoshida EM. Use of Hematopoietic Growth Factors as Adjuvant Therapy for Anemia and Neutropenia in the Treatment of Hepatitis C. Ann Pharmacother 2007;41:268-75. [DOI: 10.1345/aph.1h169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
75 Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada. J Urban Health 2004;81:428-47. [PMID: 15273266 DOI: 10.1093/jurban/jth128] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
76 [DOI: 10.1101/2020.10.15.340612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Libri NA, Barker SJ, Rosenberg WM, Semper AE. A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C. J Viral Hepat 2009;16:315-24. [PMID: 19243499 DOI: 10.1111/j.1365-2893.2008.01011.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
78 Matsunami K, Nishida N, Kaneko N, Ikeo K, Toyo-Oka L, Takeuchi H, Matsuura K, Tamori A, Nomura H, Yoshiji H, Imamura M, Masaki N, Hayakawa T, Ide T, Shimada N, Ikeda F, Hino K, Nishiguchi S, Okuse C, Nojiri S, Sawamoto K, Tokunaga K, Joh T, Tanaka Y. Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C. PLoS One 2016;11:e0164418. [PMID: 27723809 DOI: 10.1371/journal.pone.0164418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
79 Semmo N, Müllhaupt B, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Semela D. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. PLoS One 2020;15:e0241267. [PMID: 33147283 DOI: 10.1371/journal.pone.0241267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Kiser JJ. Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice 2009;22:405-18. [DOI: 10.1177/0897190008328695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Liu Q, Bengmark S, Qu S. Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis. BMC Gastroenterol 2010;10:49. [PMID: 20487553 DOI: 10.1186/1471-230X-10-49] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
82 Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008;103:905-18. [PMID: 18422827 DOI: 10.1111/j.1360-0443.2008.02188.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
83 Evon DM, Golin CE, Ruffin R, Fried MW. Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C. Contemp Clin Trials Commun 2017;6:85-96. [PMID: 29082334 DOI: 10.1016/j.conctc.2017.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Huckans MS, Loftis JM, Blackwell AD, Linke A, Hauser P. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders. Subst Abuse Treat Prev Policy 2007;2:4. [PMID: 17222348 DOI: 10.1186/1747-597X-2-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Sherman KE. Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach. Clin Infect Dis 2012;55:1236-41. [PMID: 22843782 DOI: 10.1093/cid/cis628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Sato A, Yamauchi M, Yamada T, Kumano R, Adachi K, Ishii T, Hayashi M, Kumon D. Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia. Clin J Gastroenterol 2014;7:355-60. [PMID: 25132867 DOI: 10.1007/s12328-014-0500-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Rudd MT, McCauley JA, Butcher JW, Romano JJ, McIntyre CJ, Nguyen KT, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ. Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure. ACS Med Chem Lett 2011;2:207-12. [PMID: 24900304 DOI: 10.1021/ml1002426] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
88 Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350-1359. [PMID: 16905701 DOI: 10.1136/gut.2005.076646] [Cited by in Crossref: 439] [Cited by in F6Publishing: 387] [Article Influence: 29.3] [Reference Citation Analysis]
89 Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S. Platelet count and sustained virological response in hepatitis C treatment. World J Hepatol. 2013;5:182-188. [PMID: 23671722 DOI: 10.4254/wjh.v5.i4.182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
90 Lin SY, Chen TC, Lu PL, Lin CY, Lin WR, Yang YH, Chen YH. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infect Dis 2014;14:705. [PMID: 25523602 DOI: 10.1186/s12879-014-0705-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
91 Endres CJ, Moss AM, Ke B, Govindarajan R, Choi DS, Messing RO, Unadkat JD. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther. 2009;329:387-398. [PMID: 19164463 DOI: 10.1124/jpet.108.145854] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
92 Williams CL. Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award. J Clin Invest 2016;126:3639-44. [PMID: 27620536 DOI: 10.1172/JCI90179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
93 Aghemo A, Rumi MG, Monico S, Banderali M, Russo A, Ottaviani F, Vigano M, D'Ambrosio R, Colombo M. Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepat Mon 2011;11:918-24. [PMID: 22308157 DOI: 10.5812/kowsar.1735143X.733] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
94 Li GJ, Sun P, Wang Q, Qian Y, Zhu K, Zhao X. Dendrobium candidum Wall. ex Lindl. attenuates CCl4-induced hepatic damage in imprinting control region mice. Exp Ther Med 2014;8:1015-21. [PMID: 25120640 DOI: 10.3892/etm.2014.1834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
95 Burchill MA, Roby JA, Crochet N, Wind-Rotolo M, Stone AE, Edwards MG, Dran RJ, Kriss MS, Gale M Jr, Rosen HR. Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy. PLoS One 2017;12:e0186213. [PMID: 29040318 DOI: 10.1371/journal.pone.0186213] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
96 Moreno-otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005;12:10-9. [DOI: 10.1111/j.1365-2893.2005.00563.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
97 Waheed MT, Sameeullah M, Khan FA, Syed T, Ilahi M, Gottschamel J, Lössl AG. Need of cost-effective vaccines in developing countries: What plant biotechnology can offer? Springerplus 2016;5:65. [PMID: 26839758 DOI: 10.1186/s40064-016-1713-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
98 Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, des Jarlais D, Braithwaite RS. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clin Infect Dis 2020;70:2652-62. [PMID: 31400755 DOI: 10.1093/cid/ciz726] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, Slev PR. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn 2011;13:446-51. [PMID: 21704279 DOI: 10.1016/j.jmoldx.2011.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
100 Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109. [PMID: 19749757 DOI: 10.1038/ng.449] [Cited by in Crossref: 1664] [Cited by in F6Publishing: 1515] [Article Influence: 138.7] [Reference Citation Analysis]
101 Yang N, Sun Q, Xu Z, Wang X, Zhao X, Cao Y, Chen L, Fan G. LC-ESI-MS/MS analysis and pharmacokinetics of GP205, an innovative potent macrocyclic inhibitor of hepatitis C virus NS3/4A protease in rats. Molecules 2015;20:4319-36. [PMID: 25756650 DOI: 10.3390/molecules20034319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
102 Murphy SM, Dweik D, McPherson S, Roll JM. Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings. Am J Drug Alcohol Abuse 2015;41:88-92. [PMID: 25490610 DOI: 10.3109/00952990.2014.983274] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
103 Moirand R, Bilodeau M, Brissette S, Bruneau J. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol 2007;21:355-61. [PMID: 17571168 DOI: 10.1155/2007/576765] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
104 Jeong SH, Jung YK, Yang JW, Park SJ, Kim JW, Kwon OS, Kim YS, Choi DJ, Kim JH. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. Clin Mol Hepatol 2012;18:360-7. [PMID: 23323251 DOI: 10.3350/cmh.2012.18.4.360] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
105 Fattovich G, Zagni I, Ribero ML, Castagnetti E, Minola E, Lomonaco L, Scattolini C, Fabris P, Boccia S, Giusti M, Abbati G, Felder M, Rovere P, Redaelli A, Tonon A, Tomba A, Montanari R, Paternoster C, Distasi M, Fornaciari G, Tositti G, Rizzo C, Suppressa S, Pantalena M, Noventa F, Tagger A. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. J Viral Hepat 2004;11:543-51. [DOI: 10.1111/j.1365-2893.2004.00538.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
106 Khattar R, Luft O, Yavorska N, Shalev I, Phillips MJ, Adeyi O, Gao D, Bartczak A, Urbanellis P, Shyu W, Zhang J, Manuel J, Levy GA, Selzner N. Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. PLoS One 2013;8:e72309. [PMID: 24146739 DOI: 10.1371/journal.pone.0072309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
107 Ahn SH, Lee HW, Kim YS, Kim JK, Han KH, Chon CY, Moon YM. Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. Gut Liver 2009;3:20-5. [PMID: 20479896 DOI: 10.5009/gnl.2009.3.1.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
108 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
109 Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. J Pharmacol Exp Ther 2009;331:287-96. [PMID: 19602549 DOI: 10.1124/jpet.109.153130] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
110 Mirza MU, Ghori NU, Ikram N, Adil AR, Manzoor S. Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors. Drug Des Devel Ther 2015;9:1825-41. [PMID: 25848219 DOI: 10.2147/DDDT.S75886] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
111 Masip M, Tuneu L, Pagès N, Torras X, Gallego A, Guardiola JM, Faus MJ, Mangues MA. Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Int J Clin Pharm 2015;37:1143-51. [PMID: 26267215 DOI: 10.1007/s11096-015-0177-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
112 Sjogren MH, Sjogren R Jr, Lyons MF, Ryan M, Santoro J, Smith C, Reddy KR, Bonkovsky H, Huntley B, Faris-Young S. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci 2007;52:1540-7. [PMID: 17406822 DOI: 10.1007/s10620-007-9757-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
113 Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
114 Witthöft T, Möller B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, Lafrenz M, Gelbmann CM, Hüppe D, Niederau C. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat. 2007;14:788-796. [PMID: 17927615 DOI: 10.1111/j.1365-2893.2007.00871.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
115 Evon DM, Esserman DE, Howell MA, Ruffin RA. Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C. Pharmacopsychiatry. 2014;47:195-201. [PMID: 25121993 DOI: 10.1055/s-0034-1385929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
116 Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, Dore GJ, Hellard ME; ATAHC Study Group. Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS One 2016;11:e0150655. [PMID: 27355323 DOI: 10.1371/journal.pone.0150655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
117 Gentile I, Viola C, Reynaud L, Borrelli F, Cerini R, Ciampi R, Piazza M, Borgia G. Case Report: Hemolytic Anemia During Pegylated IFN-α2b Plus Ribavirin Treatment for Chronic Hepatitis C: Ribavirin Is Not Always the Culprit. Journal of Interferon & Cytokine Research 2005;25:283-5. [DOI: 10.1089/jir.2005.25.283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
118 Bailey DE Jr, Barroso J, Muir AJ, Sloane R, Richmond J, McHutchison J, Patel K, Landerman L, Mishel MH. Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue. Res Nurs Health 2010;33:465-73. [PMID: 20730869 DOI: 10.1002/nur.20397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
119 Hopwood M. Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study. Psychol Health Med 2013;18:742-50. [PMID: 23458315 DOI: 10.1080/13548506.2013.774429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
120 Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol 2012;2:42-54. [PMID: 25755405 DOI: 10.1016/S0973-6883(12)60090-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
121 Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57:946-952. [PMID: 22760009 DOI: 10.1016/j.jhep.2012.06.030] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
122 Moss AM, Endres CJ, Ruiz-Garcia A, Choi DS, Unadkat JD. Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice. Mol Pharm 2012;9:2442-9. [PMID: 22812541 DOI: 10.1021/mp200647a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
123 Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat 2013;20:536-49. [PMID: 23808992 DOI: 10.1111/jvh.12079] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
124 Arizcorreta A, Márquez M, Fernández-Gutiérrez C, Guzmán EP, Brun F, Rodríguez-Iglesias M, Girón-González JA. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clin Exp Immunol 2006;146:270-7. [PMID: 17034579 DOI: 10.1111/j.1365-2249.2006.03220.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
125 Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology 2018;67:492-504. [PMID: 28873225 DOI: 10.1002/hep.29505] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
126 Baik SJ, Kim TH, Kim HI, Rhie JY. Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report. Medicine (Baltimore) 2016;95:e3782. [PMID: 27227948 DOI: 10.1097/MD.0000000000003782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
127 Chamoun-Emanuelli AM, Pecheur EI, Simeon RL, Huang D, Cremer PS, Chen Z. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother. 2013;57:2571-2581. [PMID: 23529728 DOI: 10.1128/aac.02593-12] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
128 Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 2016;13:e1002032. [PMID: 27243629 DOI: 10.1371/journal.pmed.1002032] [Cited by in Crossref: 158] [Cited by in F6Publishing: 118] [Article Influence: 31.6] [Reference Citation Analysis]
129 Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials 2012;9:102-12. [PMID: 22058086 DOI: 10.1177/1740774511427064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
130 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015;60:573-581. [PMID: 25236421 DOI: 10.1007/s10620-014-3361-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
131 Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53:1100-1108. [PMID: 21480316 DOI: 10.1002/hep.24169] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
132 Alves Couto C, Costa Faria L, Dias Ribeiro D, de Paula Farah K, de Melo Couto OF, de Abreu Ferrari TC. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C. Liver Int. 2006;26:1294-1297. [PMID: 17105597 DOI: 10.1111/j.1478-3231.2006.01361.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
133 Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, Holloway MK, Ludmerer SW, McCauley JA, McIntyre CJ. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 2010;54:305-311. [PMID: 19841155 DOI: 10.1128/aac.00677-09] [Cited by in Crossref: 111] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
134 Pomeroy JJ, Drusano GL, Rodriquez JL, Brown AN. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system. Antiviral Res 2017;146:149-52. [PMID: 28882564 DOI: 10.1016/j.antiviral.2017.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
135 Ng KJ, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Clin Interv Aging. 2016;11:1035-1041. [PMID: 27536084 DOI: 10.2147/cia.s108589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
136 Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial. Dig Dis Sci. 2008;53:2238-2245. [PMID: 18080763 DOI: 10.1007/s10620-007-0129-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
137 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Li Volti G, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol. 2011;17:4414-4420. [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
138 Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother. 2007;51:2016-2027. [PMID: 17420205 DOI: 10.1128/aac.01426-06] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
139 Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 2012;9:123. [PMID: 22713131 DOI: 10.1186/1743-422X-9-123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
140 Shalev I, Selzner N, Helmy A, Foerster K, Adeyi OA, Grant DR, Levy G. The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. Rambam Maimonides Med J 2010;1:e0004. [PMID: 23908776 DOI: 10.5041/RMMJ.10004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
141 Jonsson JR, Purdie DM, Clouston AD, Powell EE. Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. Mol Diagn Ther 2008;12:209-18. [PMID: 18652517 DOI: 10.1007/BF03256286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
142 Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006;24:1067-77. [DOI: 10.1111/j.1365-2036.2006.03089.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
143 Pellicano R, Craxi A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005;11:4484-9. [PMID: 16052676 DOI: 10.3748/wjg.v11.i29.4484] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
144 Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol. 2009;53:598-602. [PMID: 20020238 DOI: 10.1007/s10384-009-0738-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
145 Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, Parkinson T. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 2007;51:2969-78. [PMID: 17548497 DOI: 10.1128/AAC.00268-07] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
146 McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19:4-16. [PMID: 20132117 DOI: 10.1111/j.1521-0391.2009.00005.x] [Cited by in Crossref: 164] [Cited by in F6Publishing: 121] [Article Influence: 14.9] [Reference Citation Analysis]
147 Lodato F, Azzaroli F, Tamè MR, Di Girolamo M, Buonfiglioli F, Mazzella N, Cecinato P, Roda E, Mazzella G. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol. 2009;15:5449-5454. [PMID: 19916175 DOI: 10.3748/wjg.15.5449] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
148 Weigand K, Stremmel W, Encke J. Treatment of hepatitis C virus infection. World J Gastroenterol 2007;13:1897-905. [PMID: 17461488 DOI: 10.3748/wjg.v13.i13.1897] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
149 Yasutake K, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract 2012;2012:859697. [PMID: 23197979 DOI: 10.1155/2012/859697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
150 Li L, Zhou YF, Li YL, Wang LL, Arai H, Xu Y. In vitro and in vivo antioxidative and hepatoprotective activity of aqueous extract of Cortex Dictamni. World J Gastroenterol 2017;23:2912-27. [PMID: 28522909 DOI: 10.3748/wjg.v23.i16.2912] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
151 Cacopardo B, Benanti F, Pinzone MR, Nunnari G. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res Notes. 2013;6:437. [PMID: 24171974 DOI: 10.1186/1756-0500-6-437] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
152 Hsu CS, Hsu SJ, Liu WL, Chen DS, Kao JH. Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. Sci Rep. 2016;6:32303. [PMID: 27561198 DOI: 10.1038/srep32303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
153 Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, Kim KA, Kim JG. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol 2016;22:168-71. [PMID: 27044768 DOI: 10.3350/cmh.2016.22.1.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
154 Li PY, Zhou XJ, Yao L, Fang XH, Ren JN, Song JW. Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol 2012;18:6481-8; discussion p. 6487. [PMID: 23197895 DOI: 10.3748/wjg.v18.i44.6481] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Coats SJ, Garnier-Amblard EC, Amblard F, Ehteshami M, Amiralaei S, Zhang H, Zhou L, Boucle SR, Lu X, Bondada L, Shelton JR, Li H, Liu P, Li C, Cho JH, Chavre SN, Zhou S, Mathew J, Schinazi RF. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res 2014;102:119-47. [PMID: 24275341 DOI: 10.1016/j.antiviral.2013.11.008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
156 Turbide C, Soulellis C, Deschênes M, Hilzenrat N. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response? Can J Gastroenterol 2008;22:149-52. [PMID: 18299740 DOI: 10.1155/2008/213897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
157 Jones HM, Chan PL, van der Graaf PH, Webster R. Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. Br J Clin Pharmacol 2012;73:77-92. [PMID: 21689140 DOI: 10.1111/j.1365-2125.2011.04047.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
158 Rifai MA, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol. 2006;9:508-519. [PMID: 17081484 DOI: 10.1007/s11938-006-0007-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
159 Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012;6:285-95. [PMID: 22536063 DOI: 10.2147/PPA.S30111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
160 Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean J Intern Med 2018;33:670-8. [PMID: 29961309 DOI: 10.3904/kjim.2018.202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
161 Wadood A, Riaz M, Uddin R, Ul-Haq Z. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. PLoS One 2014;9:e89109. [PMID: 24551230 DOI: 10.1371/journal.pone.0089109] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
162 Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology 2010;52:1906-14. [PMID: 21064034 DOI: 10.1002/hep.23947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
163 Babudieri S, Soddu A, Murino M, Molicotti P, Muredda AA, Madeddu G, Fois AG, Zanetti S, Pirina P, Mura MS. Tuberculosis screening before anti-hepatitis C virus therapy in prisons. Emerg Infect Dis. 2012;18:689-691. [PMID: 22469015 DOI: 10.3201/eid1804.111016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
164 Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, Romano JJ, Bush KJ, Gilbert KF, McIntyre CJ, Nguyen KT, Nizi E, Carroll SS, Ludmerer SW, Burlein C, DiMuzio JM, Graham DJ, McHale CM, Stahlhut MW, Olsen DB, Monteagudo E, Cianetti S, Giuliano C, Pucci V, Trainor N, Fandozzi CM, Rowley M, Coleman PJ, Vacca JP, Summa V, Liverton NJ. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med Chem Lett 2012;3:332-6. [PMID: 24900473 DOI: 10.1021/ml300017p] [Cited by in Crossref: 134] [Cited by in F6Publishing: 105] [Article Influence: 14.9] [Reference Citation Analysis]
165 King A, Bornschlegel K, Johnson N, Rude E, Laraque F. Barriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014. Public Health Rep 2016;131:430-7. [PMID: 27252563 DOI: 10.1177/003335491613100309] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
166 Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006;66:155-174. [PMID: 16451091 DOI: 10.2165/00003495-200666020-00003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
167 Plosker GL, Keating GM. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Drugs 2004;64:2823-43. [PMID: 15563253 DOI: 10.2165/00003495-200464240-00009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
168 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol. 2015;7:616-627. [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
169 Gane EJ, DeJesus E, Janczewska E, George J, Diago M, Da Silva MH, Reesink H, Nikitin I, Hinrichsen H, Bourgeois S, Ferenci P, Shukla U, Kalmeijer R, Lenz O, Fevery B, Corbett C, Beumont M, Jessner W. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. BMC Infect Dis 2017;17:389. [PMID: 28577353 DOI: 10.1186/s12879-017-2444-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol. 2015;21:10749-10759. [PMID: 26478667 DOI: 10.3748/wjg.v21.i38.10749] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
171 Miller TR, Weiss JJ, Bräu N, Dieterich DT, Stivala A, Rivera-Mindt M. Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. J Neurovirol 2017;23:260-72. [PMID: 27896573 DOI: 10.1007/s13365-016-0494-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
172 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
173 Huang J, Zhang X, Tong J, Du J, Duan R, Yang L, Moore JH, Tao C, Chen Y. Comparing drug safety of hepatitis C therapies using post-market data. BMC Med Inform Decis Mak 2019;19:147. [PMID: 31391106 DOI: 10.1186/s12911-019-0860-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
174 Schäfer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007;16:186-201. [PMID: 18188838 DOI: 10.1002/mpr.229] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
175 Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat 2005;12:531-5. [PMID: 16108770 DOI: 10.1111/j.1365-2893.2005.00637.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
176 Pastore F, Martocchia A, Stefanelli M, Prunas P, Giordano S, Toussan L, Devito A, Falaschi P. Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J Hepatol 2016;8:83-91. [PMID: 26807204 DOI: 10.4254/wjh.v8.i2.83] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
177 Baik SJ, Kim TH, Yoo K, Moon IH, Cho MS. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report. World J Gastroenterol 2012;18:4233-6. [PMID: 22919260 DOI: 10.3748/wjg.v18.i31.4233] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
178 Wu JZ, Larson G, Walker H, Shim JH, Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005;49:2164-71. [PMID: 15917509 DOI: 10.1128/AAC.49.6.2164-2171.2005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
179 Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ; HCV Natural History Study Group. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005;100:299-307. [PMID: 15667486 DOI: 10.1111/j.1572-0241.2005.40757.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
180 Chang SC, Yang SS, Chang CC, Lin CC, Chung YC, Li TC. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health Qual Life Outcomes. 2014;12:97. [PMID: 24941994 DOI: 10.1186/1477-7525-12-97] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
181 Nguyen TH, Guedj J, Yu J, Levi M, Mentré F. Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome. CPT Pharmacometrics Syst Pharmacol 2013;2:e56. [PMID: 23863865 DOI: 10.1038/psp.2013.31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
182 Benson N, de Jongh J, Duckworth JD, Jones HM, Pertinez HE, Rawal JK, van Steeg TJ, Van der Graaf PH. Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice. Antimicrob Agents Chemother 2010;54:1179-85. [PMID: 20028817 DOI: 10.1128/AAC.00551-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
183 Yee LJ, Im K, Borg B, Yang H, Liang TJ; Virahep-C Study. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009;10:365-72. [PMID: 19387461 DOI: 10.1038/gene.2009.26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
184 Olsen DB, Davies ME, Handt L, Koeplinger K, Zhang NR, Ludmerer SW, Graham D, Liverton N, MacCoss M, Hazuda D, Carroll SS. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother 2011;55:937-9. [PMID: 21115793 DOI: 10.1128/AAC.00990-10] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
185 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases. 2015;3:807-822. [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
186 Kawamura Y, Takasaki S, Mizokami M. Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment. FEBS Open Bio 2012;2:98-102. [PMID: 23650587 DOI: 10.1016/j.fob.2012.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
187 Rondla R, Coats SJ, McBrayer TR, Grier J, Johns M, Tharnish PM, Whitaker T, Zhou L, Schinazi RF. Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs. Antivir Chem Chemother 2009;20:99-106. [PMID: 19843980 DOI: 10.3851/IMP1400] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
188 O'Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013;19:8227-37. [PMID: 24363513 DOI: 10.3748/wjg.v19.i45.8227] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
189 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
190 Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-270. [PMID: 22056542 DOI: 10.7326/0003-4819-156-4-201202210-00378] [Cited by in Crossref: 221] [Cited by in F6Publishing: 210] [Article Influence: 22.1] [Reference Citation Analysis]
191 Wang S, Qin E, Zhi Y, Hua R. Severe autoimmune hemolytic anemia during pegylated interferon plus ribavirin treatment for chronic hepatitis C: a case report. Clin Case Rep 2017;5:1490-2. [PMID: 28878911 DOI: 10.1002/ccr3.1098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 Helbling B, Jochum W, Stamenic I, Knöpfli M, Cerny A, Borovicka J, Gonvers JJ, Wilhelmi M, Dinges S, Müllhaupt B. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006;13:762-769. [PMID: 17052276 DOI: 10.1111/j.1365-2893.2006.00753.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
193 Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-bunschoten EP. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005;11:270-5. [DOI: 10.1111/j.1365-2516.2005.01083.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
194 De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 2008;28:113-22. [PMID: 18279106 DOI: 10.1089/jir.2007.0073] [Cited by in Crossref: 60] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
195 Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB. Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDS. 2011;25:533-538. [PMID: 21823907 DOI: 10.1089/apc.2011.0048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
196 Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, Mitamura K, Tanaka N, Kohda Y. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother 2004;48:3813-6. [PMID: 15388439 DOI: 10.1128/AAC.48.10.3813-3816.2004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
197 Yang JF, Kao YH, Dai CY, Huang JF, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int 2010;4:732-40. [PMID: 21286344 DOI: 10.1007/s12072-010-9208-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
198 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 12.5] [Reference Citation Analysis]
199 Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011;29:993-1003. [PMID: 22068541 DOI: 10.1038/nbt.2020] [Cited by in Crossref: 203] [Cited by in F6Publishing: 156] [Article Influence: 20.3] [Reference Citation Analysis]
200 Nucara S, Caroleo B, Guadagnino V, Perrotti N, Trapasso F. Natural history and clinical response: "it's the virus, stupid, or is it the host?". BMC Infect Dis. 2012;12 Suppl 2:S6. [PMID: 23173731 DOI: 10.1186/1471-2334-12-S2-S6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
201 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015;21:233-9. [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
202 Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P. IL28B Polymorphism Is Associated with Both Side Effects and Clearance of Hepatitis C During Interferon-Alpha Therapy. J Interferon Cytokine Res. 2010;Epub ahead of print. [PMID: 21133812 DOI: 10.1089/jir.2010.0074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
203 Bobeck DR, Schinazi RF, Coats SJ. Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther 2010;15:935-50. [PMID: 21041908 DOI: 10.3851/IMP1667] [Cited by in Crossref: 48] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
204 Sivaprasad S, Rao PN, Gupta R, Ashwini K, Reddy DN. The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India. J Clin Exp Hepatol 2012;2:112-5. [PMID: 25755419 DOI: 10.1016/S0973-6883(12)60098-X] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
205 Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci. 2010;55:579-585. [PMID: 19399621 DOI: 10.1007/s10620-009-0797-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
206 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
207 Arora S, Geppert CM, Kalishman S, Dion D, Pullara F, Bjeletich B, Simpson G, Alverson DC, Moore LB, Kuhl D, Scaletti JV. Academic health center management of chronic diseases through knowledge networks: Project ECHO. Acad Med 2007;82:154-60. [PMID: 17264693 DOI: 10.1097/ACM.0b013e31802d8f68] [Cited by in Crossref: 109] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
208 Fraser S. Hepatitis C and the limits of medicalisation and biological citizenship for people who inject drugs. Addiction Research & Theory 2010;18:544-56. [DOI: 10.3109/16066350903497551] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]